Ozempic Improves Glycemic Control, Cuts Weight in Schizophrenia Patients

(MedPage Today) — Low-dose semaglutide (Ozempic, Wegovy) improved glycemic control and weight outcomes in a randomized trial of adults whose schizophrenia was being treated with the second-generation antipsychotics clozapine or olanzapine.
The…